Cambrex’s Third-Quarter Profits Rise

Cambrex reported a 30% hike in third-quarter operating profits, to $3.5 million, on sales up 2.3%, to $54.7 million. The figures relate solely to ongoing businesses. Cambrex sold its biotechnology and biopharmaceuticals unit to Lonza in the past year. Lower sales volumes for certain generic active pharmaceutical ingredients (API) and contractual price declines for a high-volume APIs were offset partially by strong gains in sales of products based on the company’s polymeric drug delivery technology, Cambrex says. Third-quarter gross margins decreased to...

This information is only available to Chemical Week subscribers.

Forgot your user ID or password?
Click here to have it sent to you.

Email Address First Name Last Name

Not an IHS Chemical Week 24/7 member yet? Here's why you should be: Searchable online archive access of the last 2 years of Chemical Week. Print or digital magazine subscription Price and market change alerts Economic data and statistics Buyers' Guides Webcasts | whitepapers